8-K current report · filed Nov 12, 2026

PepGen Inc (PEPG) 8-K Current Report: November 12, 2026

Item 1.01Item 8.01Item EX-99.1Item EX-99.2PEPG overview

Short answer

PepGen Inc (PEPG) filed an 8-K current report with the SEC on November 12, 2026 reporting Item 1.01 (Entry into a Material Definitive Agreement), Item 8.01 (Other Events), Item EX-99.1 (Exhibit EX-99.1), Item EX-99.2 (Exhibit EX-99.2). $125.0 million common-stock offering: 25.0 million shares at $5.00 each.

PepGen Inc 8-K event analysis

AI summary of each reported item and its exhibits

Item 1.01 · Entry into a Material Definitive Agreement

  • $125.0 million common-stock offering: 25.0 million shares at $5.00 each
  • Underwriters’ 30-day option for 3.75 million additional shares, potentially increasing gross proceeds by $18.75 million
  • Estimated net proceeds $116.9 million, or $134.5 million with full option exercise
  • Funding directed to ongoing clinical development, working capital and general corporate purposes
  • Expected November 13, 2026 closing, subject to customary conditions; substantial share issuance creates dilution risk for existing holders

Item 8.01 · Other Events

  • PepGen launched a securities offering on November 10, 2026
  • Offering pricing announced November 11, 2026
  • Investors should review Exhibits 99.1 and 99.2 for security type, proceeds, dilution and offering terms

Item EX-99.1 · Exhibit EX-99.1

  • Proposed $125.0 million common-stock offering, primarily funding clinical development and corporate needs
  • Underwriters’ 30-day option could add $18.75 million, increasing potential proceeds
  • Equity financing implies shareholder dilution, with final size and terms still subject to market conditions
  • Pre-funded warrants offered to certain investors as an alternative to common stock
  • Proceeds expected to support PGN-EDODM1 development for myotonic dystrophy type 1

Item EX-99.2 · Exhibit EX-99.2

  • $125 million gross equity offering: 25,000,000 shares priced at $5.00 each
  • Potential additional dilution: underwriters hold a 30-day option for 3,750,000 shares
  • Proceeds earmarked for ongoing clinical development, working capital and general corporate purposes
  • Expected closing November 13, 2026, subject to customary conditions
  • Capital supports PGN-EDODM1 development while increasing shares outstanding and dilution risk

Generated from the filing text and exhibits; verify against the original. What 8-K item codes mean

Other PepGen Inc 8-K filings

Get the next PEPG 8-K as it lands

Follow PEPG for push alerts, or ask the research agent what this filing means.